EPIRUS Biopharmaceuticals to Present at Leerink Global Healthcare Conference

Leerink Global Healthcare Conference 2015

BOSTON--()--EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that the Company is scheduled to present a corporate overview at the Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 11:35 a.m. Eastern Time.

Links to a live audio webcast and replay of the presentation may be accessed on the EPIRUS website events page at http://ir.epirusbiopharma.com/events.cfm.

About EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceutical (NASDAQ: EPRS) is global biosimilar company focused on improving patient access to important medicines. EPIRUS’ operationally synergistic pipeline of biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab). The reference products for these product candidates – Remicade®, Humira® and Actemra®, respectively – together generated over $20 billion in global sales in 2013. The Company’s strategy for commercial success and profitability relies on targeted approaches for diverse and competitive global markets.

More information about EPIRUS can be found at www.epirusbiopharma.com.

Remicade is a registered trademark of Johnson and Johnson (www.jnj.com)

Humira is a registered trademark of AbbVie (www.abbvie.com)

Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group (www.gene.com)

Contacts

EPIRUS Biopharmaceuticals, Inc.
Jennifer Almond, +1-617-606-3288
ir@epirusbiopharma.com

EPIRUS Biopharmaceuticals, Inc.